Weiguang Biotech: The company's subcutaneous injection of human immunoglobulin has obtained approval for drug clinical trials.

Weiguang Biotech announced on March 24th that the company's subcutaneous injection of human immunoglobulin has received the "Notice of Approval for Clinical Trials of Drugs" issued by the National Medical Products Administration. Indications include primary immunodeficiency diseases such as X-linked agammaglobulinemia, common variable immunodeficiency diseases, and immunoglobulin G subclass deficiency diseases.